Golden
Senti Biosciences

Senti Biosciences

A synthetic biology company that designs, builds and tests genetic circuits for the purposes programming cell therapies. Their first therapeutic candidates are aimed at solid tumors and blood cancer and the company plans to move beyond oncology.

Edit ID  10249011 

Meredith Hanel
Meredith Hanel edited on 17 Mar 2019 7:54 pm
Edits made to:
Description (+245 characters)
Article (+728 characters)
Topic thumbnail

Senti Biosciences

A synthetic biology company that designs, builds and tests genetic circuits for the purposes programming cell therapies. Their first therapeutic candidates are aimed at solid tumors and blood cancer and the company plans to move beyond oncology.

Article

Senti has a proprietary synthetic biology platform for development of therapeutics. The company uses genetic circuits to program cell therapies so that they have localized action, sensors, dynamic responses and safety control. Senti has a design platform for synthetic gene circuits for fast design, building and testing of therapeutic circuits. 



The company aims to make gene therapies more adaptive and able to respond dynamically to disease conditions. One of their gene therapies in development is both universal and programmable, called the SUPRA CAR-T system. 

...

In Fall 2018, Gary Lee, Ph.D., previously with Sangamo Therapeutics, joined Senti as CSO. Santi’s chief financial officer Curt Herberts also comes from Sangamo.